The WHO’s statement comes about a week after Japanese scientists published research on BA.2’s genetic differences from its parent strain, which they said warrant it being labeled as a separate variant of concern with its own Greek letter.
The WHO’s Technical Advisory Group on SARS-CoV-2 Virus Evolution met Feb. 21 to discuss the latest evidence on omicron, including the new research from Japan.
“Based on available data of transmission, severity, reinfection, diagnostics, therapeutics and impacts of vaccines, the group reinforced that the BA.2 sublineage should continue to be considered a variant of concern and that it should remain classified as omicron,” the WHO said.
Public health officials worldwide should continue to monitor BA.2 as a distinct sublineage of omicron, the group said.
View WHO’s full statement here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
